Neoadjuvant Danburstotug (IMC-001) therapy in gastric, esophageal, and hepatocellular carcinoma: the NeoChance phase II study. - Bang YH; Kang D; Lee S; Kim S; Jeon I; Park E; Choi J; Song GW; Yoo MW; Song JS; Song IH; Kim YH; et al. (NPJ precision oncology, 2026)